Abstract:The rapid development of a stereoselective route for CXCR7 antagonist ACT-1004-1239 was needed, as the large-scale chromatographic separation of enantiomers was not a viable option for a resupply campaign that targeted >30 kg of API. The key to success was the stereoselective reduction of a chiral enamine derived from inexpensive (S)-α-methylbenzylamine. The reduction showed good selectivity for the desired cis-3R,4S-isomer, and the pure diastereomer (d.r. >98:2) was isolated as its TFA salt. After removal of the ethylbenzyl group and amide coupling with 5-(2,4-difluorophenyl)isoxazole-3-carboxylic acid, the enantiopure cis-3R,4S-amide was isolated. The subsequent epimerization of the 3-position adjacent to the methyl ester turned out to be a formidable challenge, as the standard conditions with NaOMe led to the formation of a thermodynamic mixture of the cis and trans isomers (final ratio of ∼1:4). Therefore, a new procedure was developed in which the methyl ester was transesterified in situ to the isopropyl ester with KOiPr in iPrOH, followed by epimerization to the trans-iPr-ester (final cis:trans ratio 5:95). After saponification with aqueous KOH, the desired trans-3S,4S-acid was isolated in overall 76% yield. After amide coupling and Boc deprotection, the final reductive amination with cyclopropanecarboxaldehyde was also vastly improved. A novel NaBH(OAc)3 solution in DMSO was used for the reaction and cleanly provided the API with high purity after simple aqueous quench without the need for any solvent switches or aqueous workups. As a proof of concept, 240 g of API was produced in house with the novel stereoselective route, which was then also used to produce over 30 kg of GMP material at an external manufacturer for Phase 2 clinical studies.

Development of a Scalable Synthesis Toward a KRAS G12C Inhibitor Building Block Bearing an All-Carbon Quaternary Stereocenter, Part 1: from Discovery Route to Kilogram-Scale Production

Atroposelective Negishi Coupling Optimization Guided by Multivariate Linear Regression Analysis: Asymmetric Synthesis of KRAS G12C Covalent Inhibitor GDC-6036

Building a Quaternary Stereogenic Center on Dihydroazaindole Carboxylic Acid through Scalable Process Development

Development of a Practical Telescoped Process to Prepare (P)-7-(2-amino-6-fluorophenyl)-4-hydroxy-6-(trifluoromethyl)pyrido[3,4-d]pyrimidin-8(7h)-one: a Key Intermediate of KRASG12C Inhibitor GH35

Development Of A Concise, Scalable Synthesis Of A Ccr1 Antagonist Utilizing A Continuous Flow Curtius Rearrangement

Development of a Kilogram-Scale Chemical Process for a Chiral Spirocyclic Isoxazolone

Lab-Scale Preparation of a Novel Carbocyclic Chemokine Receptor Antagonist

Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195)

Lab-Scale Preparation of a Novel Cyclopenta[b]furan Chemokine Receptor Antagonist

Development of a Scalable, Stereoselective Second-Generation Route for CXCR7 Antagonist ACT-1004-1239 via Chiral Enamine Reduction and a Novel Telescoped Sequence of Transesterification, cis -to- trans Epimerization, and Saponification

Synthesis of chiral building blocks for use in drug discovery

Evolution of the Manufacturing Route towards a Key Benzothiophen‐2‐yl‐Boronic Acid Building Block of Rogaratinib

Development of a Scalable Synthesis of Mevidalen (LY3154207), an Orally Available Positive Allosteric Modulator of the Human Dopamine D1 Receptor

Process Development of a Novel Azetidinyl Ketolide Antibiotic

Scalable Synthesis of C5aR1 Antagonist ACT-1014-6470 via N 7 -Selective Reductive Amination of an Unprotected Pyrazole Starting Material and Intramolecular Urea Formation with 1,1′-Carbonyl-di(1,2,4-triazol) (CDT)

Development of A Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist Bi 653048 Bs H3po4

Process Development and Scale-Up of a Novel Atypical DAT Inhibitor ( S )-CE-123

Process Development and Manufacture of the Core Starting Material of Adagrasib (MRTX849)

Manufacturable Process of a Novel EGFR Inhibitor (larotinib) for the Treatment of ESCC

Multigram-scale synthesis of volasertib, an inhibitor of polo-like kinases in clinical evaluation

Stereochemical Editing via Coupled Epimerization and Optical Resolution to Sustainably Manufacture a Key Adagrasib Building Block